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Post-Discharge Prophylaxis With
Rivaroxaban Reduces Fatal and
Major Thromboembolic Events in
Medically Ill Patients
Alex C. Spyropoulos, MD,a Walter Ageno, MD,b Gregory W. Albers, MD,c C. Gregory Elliott, MD,d
Jonathan L. Halperin, MD,e William R. Hiatt, MD,f,g Gregory A. Maynard, MD,h P. Gabriel Steg, MD,i,j
Jeffrey I. Weitz, MD,k Wentao Lu, PHD,l Theodore E. Spiro, MD,m Elliot S. Barnathan, MD,l Gary. E. Raskob, PHDn

ABSTRACT
BACKGROUND Hospitalized acutely ill medical patients are at risk for fatal and major thromboembolic events. Whether
use of extended-duration primary thromboprophylaxis can prevent such events is unknown.
OBJECTIVES The purpose of this study was to evaluate whether extended-duration rivaroxaban reduces the risk of
venous and arterial fatal and major thromboembolic events without signiﬁcantly increasing major bleeding in acutely ill
medical patients after discharge.
METHODS MARINER (A Study of Rivaroxaban [JNJ-39039039] on the Venous Thromboembolic Risk in Post-Hospital
Discharge Patients) studied acutely ill medical patients with additional risk factors for venous thromboembolism (VTE).
Medically ill patients with a baseline creatinine clearance $50 ml/min were randomized in a double-blind fashion to
rivaroxaban 10 mg or placebo daily at hospital discharge for 45 days. Exploratory efﬁcacy analyses were performed with
the intent-to-treat population including all data through day 45. Time-to-event curves were calculated using the KaplanMeier method. A blinded independent committee adjudicated all clinical events.
RESULTS In total, 4,909 patients were assigned to rivaroxaban and 4,913 patients to placebo. The mean age was 67.8
years, 55.5% were men, mean baseline creatinine clearance was 87.8 ml/min, and mean duration of hospitalization was
6.7 days. The pre-speciﬁed composite efﬁcacy endpoint (symptomatic VTE, myocardial infarction, nonhemorrhagic
stroke, and cardiovascular death) occurred in 1.28% and 1.77% of patients in the rivaroxaban and placebo groups,
respectively (hazard ratio: 0.72; 95% conﬁdence interval: 0.52 to 1.00; p ¼ 0.049), whereas major bleeding occurred in
0.27% and 0.18% of patients in the rivaroxaban and placebo groups, respectively (hazard ratio: 1.44; 95% conﬁdence
interval: 0.62 to 3.37; p ¼ 0.398).
CONCLUSIONS Extended-duration rivaroxaban in hospitalized medically ill patients resulted in a 28% reduction
in fatal and major thromboembolic events without a signiﬁcant increase in major bleeding. (A Study of
Rivaroxaban [JNJ-39039039] on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients [MARINER];
NCT02111564) (J Am Coll Cardiol 2020;75:3140–7) © 2020 The Authors. Published by Elsevier on behalf of the
American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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large proportion of the approximately 8

excluding those at high risk of bleeding.

ABBREVIATIONS

million acute medically ill patients each

Although the trial did not demonstrate a

AND ACRONYMS

year in the United States are at risk for

reduction in the primary endpoint of symp-

venous thromboembolism (VTE) (1). Hospitalization

tomatic VTE and VTE-related death, key

is considered the single most important risk factor

secondary efﬁcacy endpoints revealed a 56%

for developing these events (2), and the risk of VTE

reduction in symptomatic VTE and a 27%

continues beyond hospitalization, especially within

reduction in symptomatic VTE and all-cause

the ﬁrst 6 weeks after discharge (3). Although the

mortality. The lower 7.5 mg dose of rivarox-

CI = conﬁdence interval
CrCl = creatinine clearance
HR = hazard ratio
MI = myocardial infarction
VTE = venous
thromboembolism

relationship between VTE and atherothrombosis/

aban used in patients with moderate renal

arterial thromboembolism has been known for some

insufﬁciency was found to be ineffective (8), unlike

time due to the shared mechanisms of inﬂammation,

the dose of 10 mg, which had previously been

hypercoagulability, and endothelial injury inherent

demonstrated to be effective in the MAGELLAN

to both disease processes and due to common

(Venous Thromboembolic Event [VTE] Prophylaxis in

patient-level risk factors, such as obesity, dyslipide-

Medically

mia, and tobacco use (4,5), it has only recently been

extended thromboprophylaxis in medically ill pa-

Ill

Patients;

NCT00571649)

study

of

appreciated that medically ill patients are also at

tients (9). A pre-speciﬁed secondary endpoint of the

increased risk of arterial thromboembolic events in

trial was fatal and major venous and arterial throm-

the post-hospital discharge period (6,7). Retrospec-

boembolic events (8). Therefore, this exploratory

tive data also reveal that extended duration of a pro-

analysis focused on whether rivaroxaban could

phylactic dose of a direct oral anticoagulant in

reduce the incidence of fatal and major thromboem-

medically ill patients may reduce the risk of fatal

bolic events in patients treated with 10 mg daily of

and major arterial thromboembolism by 30% to 50%

rivaroxaban compared with placebo when given to

(6,7).

acutely ill medical patients at the time of discharge
SEE PAGE 3148

The previously reported MARINER trial (A Study of

for 45 days.

METHODS

Rivaroxaban [JNJ-39039039] on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients)

STUDY DESIGN. The MARINER protocol and study

(NCT02111564) (8), randomized medically ill patients

results have been reported previously (8,10). The

with additional risk factors for VTE to extended-

protocol was approved by local ethics committees,

duration rivaroxaban (10 mg once daily for 45 days

and all subjects provided written informed consent.

or 7.5 mg once daily for those with a creatinine

Brieﬂy, MARINER was a multicenter, prospective,

clearance between 30 and 50 ml/min) or placebo after

randomized,

double-blind,

placebo-controlled,
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risk of bleeding were excluded from the study. The

T A B L E 1 Characteristics of Patients at Baseline (ITT)

Male

primary hypothesis was that rivaroxaban was supe-

Rivaroxaban
10 mg
(n ¼ 4,909)

Placebo
(n ¼ 4,913)

55.3

55.7

thrombosis and nonfatal pulmonary embolism [PE])

rior to placebo for the prevention of the composite of
symptomatic

VTE

(lower

extremity

deep

vein

Mean age, yrs

67.8

67.7

and VTE-related death (death due to PE or death in

White race

96.3

96.7

which PE could not be ruled out). The primary hy-

Mean BMI, kg/m2

29.5

29.3

pothesis of this exploratory analysis was that rivar-

Heart failure

37.4

37.0

Respiratory insufﬁciency or exacerbation of chronic
obstructive pulmonary disease

27.6

28.0

Ischemic stroke

15.5

15.7

and cardiovascular (CV) death in the stratum of pa-

Infectious disease

17.9

17.7

tients with a baseline CrCl $50 ml/min receiving the

1.5

1.7

10 mg dose of rivaroxaban.

6.7

6.7

D-dimer >2 upper limit of normal during the index
hospitalization

68.7

68.7

Mean baseline CrCl

87.9

87.8

interval (CI) for the 10 mg rivaroxaban dose versus

Baseline aspirin

51.9

49.1

placebo were provided based on the Cox proportional

Current or former smoker

48.2

48.3

Baseline statin

41.9

41.4

Baseline U.S.-approved thromboprophylaxis

71.2

71.5

History of hypertension

78.2

78.8

regardless of the actual treatment received. All sta-

History of diabetes

29.5

27.9

tistical tests were interpreted at a nominal (without

History of heart failure

47.9

47.5

adjustment for multiplicity) 2-sided signiﬁcance level

History of coronary artery disease

32.1

31.1

of 0.05, and all CIs at a nominal 2-sided level of 95%.

History of hyperlipidemia

20.5

19.6

The Kaplan-Meier method was used to summarize the

History of cancer

8.0

8.7

time-to-event analyses.

2

35.5

36.0

EFFICACY AND SAFETY OUTCOMES. The efﬁcacy

3

29.3

27.4

outcome of the composite of symptomatic VTE,

$4

35.1

36.4

MI, nonhemorrhagic stroke, and CV death was a

Reason for hospitalization

Inﬂammatory disease
Mean duration of index hospitalization, days

oxaban was superior to placebo for the prevention of
the pre-speciﬁed composite of symptomatic VTE,
myocardial infarction (MI), nonhemorrhagic stroke,

STATISTICAL METHODS. The point estimate for the

hazard ratio (HR) and corresponding 95% conﬁdence

IMPROVE VTE risk factor score

hazards model. Patients were analyzed according to
the treatment group they were randomized to,

pre-speciﬁed secondary endpoint, and individual
Values are % or mean (where indicated). Note: intention-to-treat (ITT): all randomized patients
who had valid signed informed consent. U.S.-approved thromboprophylaxis includes enoxaparin,
dalteparin, and heparin. Patients who have both U.S.-approved and other baseline use of
thromboprophylaxis are included in the U.S.-approved thromboprophylaxis category.
BMI ¼ body mass index; CrCl ¼ creatine clearance; IMPROVE VTE ¼ International Medical
Prevention Registry on Venous Thromboembolism venous thromboembolism model.

outcomes were veriﬁed by objective testing and
autopsy reports, where available using standardized
deﬁnitions (8). The principal safety outcome of major
bleeding was based on the International Society on
Thrombosis and Haemostasis bleeding criteria and

event-driven

study

that

evaluated

rivaroxaban

(10 mg daily in patients with creatinine clearance
[CrCl] $50 ml/min or 7.5 mg daily with CrCl 30
to <50 ml/min at baseline) versus placebo for 45 days
beyond hospital discharge to prevent symptomatic
VTE and VTE-related death in acutely ill medical patients. Eligible patients were 40 years of age or older,

included fatal bleeding, bleeding into a critical organ,
or bleeding that led to a drop of $2 g/dl of hemoglobin
or a transfusion of 2 U or more of blood. Bleeding
events were analyzed based on time from randomization to the ﬁrst occurrence. All endpoints were adjudicated by a blinded clinical events committee.

RESULTS

were hospitalized for at least 3 and no more than 10
consecutive days prior to randomization for a speciﬁc

BASELINE CHARACTERISTICS. A total of 4,909 pa-

acute medical illness, and had other risk factors for

tients were assigned to the rivaroxaban 10 mg group

VTE. Other VTE risk factors were demonstrated by a

(baseline CrCl $50 ml/min) and 4,913 patients to

total modiﬁed IMPROVE (International Medical Pre-

matching placebo and are included in the intent-to-

vention Registry on Venous Thromboembolism) VTE

treat (ITT) population. The ITT analysis set included

risk score of $4 or VTE risk score of 2 or 3 with

all randomized patients who had valid informed

D-dimer >2 the upper limit of normal. Patients

consent. Baseline characteristics were well balanced

received thromboprophylaxis during the index hos-

between treatment groups (Table 1). The mean age of

pitalization with low-molecular-weight heparin or

this population was 67.8 years, 55.5% were men, and

unfractionated heparin. Patients with an increased

96.5% were white. The most frequently reported
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T A B L E 2 Time to First Occurrence of Composite Outcome and Components (ITT)

Rivaroxaban 10 mg vs. Placebo
Endpoint

Composite of symptomatic VTE (DVT and nonfatal PE),
MI, nonhemorrhagic stroke, CV death

Rivaroxaban 10 mg

Placebo

HR (95% CI)*

p Value†

63/4,909 (1.28)

87/4,913 (1.77)

0.72 (0.52–1.00)

0.049

Symptomatic lower extremity DVT

2/4,909 (0.04)

10/4,913 (0.20)

0.20 (0.04–0.91)

—

Symptomatic nonfatal PE

4/4,909 (0.08)

11/4,913 (0.22)

0.36 (0.12–1.14)

—
—

MI

13/4,909 (0.26)

8/4,913 (0.16)

1.62 (0.67–3.92)

Nonhemorrhagic stroke

13/4,909 (0.26)

24/4,913 (0.49)

0.54 (0.28–1.06)

—

CV death

39/4,909 (0.79)

42/4,913 (0.85)

0.93 (0.60–1.44)

—

Values are n/N (%) unless otherwise indicated. CV death includes VTE-related death. All events were adjudicated by the clinical event committee. Intention-to-treat (ITT): all
randomized patients who had valid signed informed consent. *HRs (95% CIs) are from Cox proportional hazards model with treatment as the only covariate. †The p value (2sided) for superiority of rivaroxaban versus placebo from Cox proportional hazards model.
CI ¼ conﬁdence interval; CV ¼ cardiovascular; DVT ¼ deep vein thrombosis; HR ¼ hazard ratio; MI ¼ myocardial infarction; PE ¼ pulmonary embolism; VTE ¼ venous
thromboembolism.

admitting diagnosis for patients overall was heart

patients. Major bleeding occurred in 13 (0.27%) and 9

failure with reduced ejection fraction #45% (37.2%)

(0.18%) patients in the rivaroxaban and placebo

and the mean duration of hospitalization was 6.7 

groups, respectively (HR: 1.44; 95% CI: 0.62 to 3.37;

2.4 days. Overall, 52.0% of patients had a baseline

p ¼ 0.398) (Table 3). When evaluated by type of

CrCl level $80 ml/min and 47.9% had a baseline CrCl

major bleeding, a greater proportion of patients

50 to <80 ml/min with a mean baseline creatine

receiving 10 mg rivaroxaban than placebo had major

clearance of 87.8 ml/min. At baseline, aspirin was

bleeding events with a fall in hemoglobin of $2 g/dl

used in 51.9% of patients; a statin was used by 41.7%.

(0.22% and 0.12%, respectively) and transfusion

A history of reduced or preserved ejection fraction

of >2 U of packed red blood cells (or whole blood)

heart failure (47.7%), coronary artery disease (31.6%),

than patients in the placebo group (0.16% and 0.06%,

diabetes (28.7%), and hyperlipidemia (20.0%) were

respectively). There were 2 critical site bleeds in each

also common in the population. A history of cancer

group, and 2 fatal bleeds in the rivaroxaban group. A

was reported by 8.3% of patients, while patients with

Kaplan-Meier analysis of the timing of major bleeding

active

occurrence is shown in the Central Illustration.

cancer

undergoing

chemotherapy

were

excluded. Total modiﬁed IMPROVE VTE risk factor
scores of 2, 3, and $4 were reported for 35.8%, 28.4%,

DISCUSSION

and 35.8% of patients, respectively.
EFFICACY AND SAFETY OUTCOMES. The composite

This analysis demonstrates that compared with pla-

endpoint of symptomatic VTE, MI, nonhemorrhagic

cebo, extended-duration thromboprophylaxis with

stroke, and CV death occurred in 1.28% of patients

low-dose rivaroxaban (10 mg daily) started after

randomized to rivaroxaban and in 1.77% of those on

hospital discharge leads to a signiﬁcant 28% reduc-

placebo (HR: 0.72; 95% CI: 0.52 to 1.00; p ¼ 0.049)

tion in the combined risk of fatal and major throm-

(Table 2). All incidence of the components of the

boembolic events without a signiﬁcant increase in

composite endpoint, except MI, numerically tended

major bleeding in hospitalized medically ill patients.

to favor rivaroxaban. Symptomatic lower-extremity

This beneﬁt appears to begin after the ﬁrst week of

deep vein thrombosis and symptomatic nonfatal PE

treatment and continues until the end of study at

showed greater risk reduction with rivaroxaban with

45 days. There was a 0.49% absolute risk reduction of

a relative risk reduction of 80% (HR: 0.20; 95% CI:

efﬁcacy events and a 0.09% absolute increase in the

0.04 to 0.91) and 62% (HR: 0.36; 95% CI: 0.12 to 1.14),

risk of major bleeding, suggesting a net clinical

respectively (Table 2). Kaplan-Meier curves for the

beneﬁt.

composite of symptomatic VTE, MI, nonhemorrhagic
stroke,

and

CV

death

are

presented

in

the

Central Illustration.

A meta-analysis of arterial thrombosis (including
MI and ischemic stroke) of older studies involving
w11,000 medically ill inpatients receiving heparin-

The bleeding analysis used the safety population,

based prophylaxis did not ﬁnd a reduction of these

which for the 10 mg dose included 4,890 in both the

events compared with control subjects (odds ratio:

rivaroxaban and placebo groups for a total of 9,780

1.95; 95% conﬁdence interval: 0.89 to 4.27) (11). The
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C E NT R AL IL L U STR AT IO N Major Efﬁcacy and Safety Outcomes Over Time

2.0
Cumulative Event Rate (%)

A

p value
0.049

HR (95% CI)
0.72 (0.52–1.00)

1.5

1.0

0.5

0.0

Subjects at risk
Rivaroxaban

0

5

10

4,909

4,895

4,883

4,873

4,861

4,852

4,913

4,896

4,881

4,866

4,852

4,835

Placebo

35

40

45

4,846

4,833

4,827

0

4,821

4,815

4,802

0

35

40

45

2.0
Cumulative Event Rate (%)

B

15
20
25
30
Days Since Randomization

p value
0.398

HR (95% CI)
1.44 (0.62–3.37)

1.5

1.0

0.5

0.0

Subjects at risk
Rivaroxaban
Placebo

0

5

10

15
20
25
30
Days Since Randomization

4,890

4,833

4,777

4,744

4,701

4,656

4,637

4,611

4,588

4,548

4,890

4,839

4,764

4,724

4,693

4,642

4,616

4,597

4,568

4,528

Spyropoulos, A.C. et al. J Am Coll Cardiol. 2020;75(25):3140–7.
(A) Time to ﬁrst occurrence of composite: venous thromboembolism, myocardial infarction, nonhemorrhagic stroke, and cardiovascular death up to day 45 (rivaroxaban
10 mg daily vs. placebo; intention to treat). Includes all data from randomization to day 45 (inclusive). Patients who do not have events are censored on the minimum of
last visit before or on death or day 45. (B) Time to ﬁrst occurrence of major bleeding on-treatment (rivaroxaban 10 mg daily vs. placebo; safety population).
On-treatment includes all data from randomization to 2 days after the last dose of the study drug (inclusive). Subjects who do not have events are censored on the
minimum of last visit before or on death, or last dose þ2 days. CI ¼ conﬁdence interval; HR ¼ hazard ratio.
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authors concluded that arterial thrombotic events
appeared to be under-reported in trials of venous

T A B L E 3 Time to First Occurrence of Major Bleeding Event, On-Treatment

(Safety Analysis Set)

thromboprophylaxis, and they recommended sysRivaroxaban 10 mg
vs. Placebo

tematic monitoring of such events in future trials. In
the MARINER study, data on arterial events were

Rivaroxaban 10 mg

Placebo

HR (95% CI)*

p Value†

ISTH major bleeding

13/4,890 (0.27)

9/4,890 (0.18)

1.44 (0.62–3.37)

0.398

Fall in hemoglobin
of $2 g/dl

11/4,890 (0.22)

6/4,890 (0.12)

1.83 (0.68–4.95)

—

8/4,890 (0.16)

3/4,890 (0.06)

2.66 (0.71–10.04)

—

laxis with rivaroxaban in medically ill patients may

Transfusion of $2 U
of packed red blood
cells or whole blood

lead to reductions in arterial thromboembolic events

Critical site

2/4,890 (0.04)

2/4,890 (0.04)

1.00 (0.14–7.10)

—

(primarily ischemic stroke) as well as a reduction in

Fatal outcome

2/4,890 (0.04)

0/4,890

NA

NA

captured using a standardized data collection form,

Endpoint

and all suspected events were centrally adjudicated
using pre-speciﬁed criteria. Although exploratory,
our analysis suggests that extended thromboprophy-

symptomatic VTE. Such a ﬁnding is in line with the
results of the APEX trial (12), which in post hoc analyses revealed a w30% reduction in fatal and irreversible ischemic events (including PE, MI, nonfatal
ischemic stroke, or CV death) without an increase in

Values are n/N (%) unless otherwise indicated. All adjudicated by the clinical event committee. Safety analysis
set: all intention-to-treat patients who take at least 1 dose of study drug. *HRs (95% CIs) are from Cox proportional hazards model with treatment as the only covariate. †p value (2-sided) for superiority of rivaroxaban vs.
placebo from Cox proportional hazards model.
ISTH ¼ International Society on Thrombosis and Haemostasis; NA ¼ not applicable; other abbreviations as in
Table 2.

fatal or intracranial hemorrhage, and a w50% reduction in ischemic stroke with betrixaban compared
with placebo (6,7). A recent pooled analysis of both

by data from the MARINER pharmacokinetic sub-

the MARINER and MAGELLAN trials of extended

study in patients receiving the 10 mg dose (9).

thromboprophylaxis with the 10 mg dose of rivarox-

Our ﬁndings may have important implications for

aban also revealed a signiﬁcant 22% reduction in all-

the population of medically ill patients now that

cause mortality and major thromboembolic events,

rivaroxaban is approved for extended post-hospital

including symptomatic VTE, MI, and nonhemorrhagic

discharge thromboprophylaxis in at-risk medically

stroke (1.80% vs. 2.31%; HR: 0.78; 95% CI: 0.63 to

ill patients in the United States. A previous beneﬁt/

0.97; p ¼ 0.024), without an increase in critical site or

risk assessment of a low-bleed risk subpopulation of

fatal bleeding (13).

the MAGELLAN trial revealed that extended throm-

The association between VTE and arterial throm-

boprophylaxis with the 10 mg dose of rivaroxaban

boembolic disease has been well-established (5,14).

would lead to 21 fewer fatal and major thromboem-

Underlying common mechanisms of both VTE and

bolic events per 10,000 patients at the expense of 9

arterial

primary

more critical site or fatal bleeds, with a number

thromboprophylaxis using an established anticoagu-

needed to treat of 481 and number needed to harm of

lant regimen, possibly against a background of anti-

1,061 (19). In the large population of at-risk medically

platelet therapy and given for a sufﬁcient duration,

ill patients each year, this strategy would have the

can be effective in reducing both types of events. An

potential to prevent 12,000 fatal and major throm-

analysis of MARINER data in the subset of patients

boembolic events annually at the cost of one-fourth

receiving rivaroxaban plus aspirin, although not

to one-half that number of major or fatal bleeds (19).

randomized for aspirin use and hypothesis gener-

STUDY

ating, suggested greater efﬁcacy with rivaroxaban

include its exploratory nature, because the MARINER

thromboembolism

suggest

that

LIMITATIONS. Limitations

of

this

study

plus aspirin in reducing symptomatic VTE and VTE-

study failed to meet its primary efﬁcacy endpoint. We

related death (15). In the COMPASS (Rivaroxaban for

cannot exclude potential under-reporting of arterial

the Prevention of Major Cardiovascular Events in

thromboembolic events as the trial was powered to

Coronary or Peripheral Artery Disease; NCT01776424)

assess the risk of VTE, although this is unlikely

trial, a very large study that compared 2.5 mg twice

because a standardized case report form was used

daily of rivaroxaban plus 100 mg aspirin daily with

with careful study oversight of outcomes and central

100 mg aspirin daily alone in patients with chronic

adjudication of all of these events. In addition, the

coronary artery disease or peripheral artery disease,

composite endpoint was driven primarily by a

rivaroxaban plus aspirin signiﬁcantly reduced the

reduction in symptomatic VTE and ischemic stroke.

incidence of CV death, stroke, and MI by 24% (16).

Although event rates may be considered low (<2.0%),

This dose of rivaroxaban would be predicted to pro-

the

duce trough levels similar to those achieved with

continued to accumulate after the study period of

10 mg once daily (17,18); this ﬁnding was supported

45 days such that we cannot exclude the possibility

time-to-event

curves

suggest

that

events
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that rivaroxaban continues to reduce these events

authors also thank Traci Weber, who supported the

over a longer period of time. Our study also excluded

writing of this manuscript.

subjects with moderate renal insufﬁciency because
the reduced dose chosen (7.5 mg) was deemed inad-
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equate. However, a recent study has demonstrated
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oxaban with a favorable beneﬁt risk proﬁle (9). As

Institute for Medical Research, and Department of

approximately 50% of our study population had

Medicine, Anticoagulation and Clinical Thrombosis

baseline aspirin use, an important antithrombotic
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synergy between prophylactic dose rivaroxaban and
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antiplatelet therapy cannot be excluded, and there
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are mechanistic implications of such a synergistic
antithrombotic strategy that may lead to reductions

PERSPECTIVES

in CV outcomes (15,16).
COMPETENCY IN PATIENT CARE AND

CONCLUSIONS

PROCEDURAL SKILLS: Hospitalized medically ill

Our analysis suggests that in at-risk medically ill patients

who

are

discharged

from

the

hospital,

patients remain at risk of venous and arterial thromboembolism, especially within the ﬁrst 6 weeks after

extended-duration rivaroxaban at the 10 mg daily

discharge. Treatment with rivaroxaban (10 mg once

dose leads to a signiﬁcant risk reduction in a com-

daily) for up to 45 days beyond discharge of patients at

posite of fatal and major thromboembolic events—

higher risk of thromboembolism and lower risk of

including symptomatic VTE, MI, nonhemorrhagic

bleeding reduces the incidence of fatal and major

stroke, and CV death—without a signiﬁcant increase

thromboembolism without increasing major bleeding.

in major bleeding, compared with placebo. These data
suggest that in properly selected patients at risk for
VTE and at low risk for bleeding, that extendedduration rivaroxaban at 10 mg has a favorable
beneﬁt risk proﬁle.

TRANSLATIONAL OUTLOOK: Prospective studies
of patients hospitalized with coronavirus disease2019 pneumonia are needed to conﬁrm the beneﬁt
and safety of extended antithrombotic therapy in that
speciﬁc subset of medically ill patients.
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